深圳创新药十项新锐成果发布，覆盖肿瘤、心脑血管等重大领域

Core Insights - The Shenzhen Innovation Drug Development Forum showcased ten innovative drug results, highlighting Shenzhen's strength in biopharmaceutical innovation and the integration of AI in drug development [3][4]. Group 1: Innovative Drug Results - AS1501, developed by Shenzhen University of Technology and a local pharmaceutical company, is the world's first TRAIL-DR5 pathway blocker for severe liver conditions, currently in clinical phase II, with no direct global competitors [3][4]. - BrAD-R13, a small molecule drug targeting Alzheimer's disease, has completed clinical phase I and is moving towards product transformation, aiming to provide effective treatment options for millions of patients [4]. - The AI-driven autonomous experimental platform by Crystal Technology has signed a collaboration order worth $59.9 billion with overseas pharmaceutical companies, marking a significant achievement in AI drug development [5]. Group 2: Collaborations and Innovations - A collaboration agreement worth $16.4 billion was established between Pruijng and Kite for the development of the first CAR-T therapy pipeline authorized for external use, indicating a new phase in China's in-situ editing therapy [5]. - Xinlitai launched a national class 1 innovative drug, Xiliting, for type 2 diabetes treatment, characterized by rapid oral absorption and high selectivity [5]. - Leiman Bio developed a low-dose cell therapy that can achieve 100% complete remission for advanced hematological tumors and systemic lupus erythematosus, significantly reducing production costs and treatment cycles [5].